RECURRENT HAIRY CELL LEUKEMIA
Clinical trials for RECURRENT HAIRY CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HAIRY CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT HAIRY CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo targets rare leukemia
Disease control Recruiting nowThis study tests a two-step treatment for hairy cell leukemia, a rare blood cancer. First, patients receive chemotherapy (cladribine) to kill cancer cells, then an immunotherapy drug (rituximab) to help the immune system attack any remaining cells. The goal is to see if adding ri…
Matched conditions: RECURRENT HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo aims to tackle hairy cell leukemia
Disease control Recruiting nowThis study tests a combination of two drugs, tovorafenib and rituximab, in people with hairy cell leukemia that has returned or not responded to treatment, and also compares it to standard therapy for newly diagnosed patients. Tovorafenib blocks a protein that helps cancer grow, …
Matched conditions: RECURRENT HAIRY CELL LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for rare leukemia: targeted pill tackles relapse
Disease control Recruiting nowThis study tests a pill called venetoclax for people whose hairy cell leukemia has returned after prior treatment. The drug blocks a protein that cancer cells need to survive. About 20 adults will take venetoclax to see if it shrinks tumors and improves blood counts, with the goa…
Matched conditions: RECURRENT HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC